Get the Stockscreener App
13.60
2.37%
-0.33
After Hours:
13.60
Amylyx Pharmaceuticals Inc stock is traded at $13.60, with a volume of 890.92K.
It is down -2.37% in the last 24 hours and up +1.34% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
See More
Previous Close:
$13.93
Open:
$13.88
24h Volume:
890.92K
Relative Volume:
0.53
Market Cap:
$1.21B
Revenue:
$-249.00K
Net Income/Loss:
$-187.60M
P/E Ratio:
-5.44
EPS:
-2.5
Net Cash Flow:
$-201.88M
1W Performance:
-4.43%
1M Performance:
+1.34%
6M Performance:
+155.64%
1Y Performance:
+141.13%
1-Day Range:
$13.30
$13.96
1-Week Range:
$13.30
$14.41
52-Week Range:
$2.865
$16.96
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Industry
Phone
617-683-0917
Address
43 THORNDIKE STREET, CAMBRIDGE
Compare AMLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
13.60 | 1.49B | -249.00K | -187.60M | -201.88M | -2.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Guggenheim | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| May-30-25 | Initiated | TD Cowen | Buy |
| Apr-07-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
What the charts say about Amylyx Pharmaceuticals Inc. today2025 Top Gainers & Scalable Portfolio Growth Methods - newser.com
Is Amylyx Pharmaceuticals Inc. stock attractive for long term wealth buildingTrade Ideas & Verified Technical Trade Signals - newser.com
Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences - The Globe and Mail
Will Amylyx Pharmaceuticals Inc. stock benefit from commodity pricesMarket Volume Report & Advanced Swing Trade Entry Plans - newser.com
Real time social sentiment graph for Amylyx Pharmaceuticals Inc.July 2025 Macro Moves & Accurate Intraday Trade Tips - newser.com
Real time alert setup for Amylyx Pharmaceuticals Inc. performanceWeekly Investment Recap & Fast Gain Stock Trading Tips - newser.com
Is Amylyx Pharmaceuticals Inc. stock a defensive play in 2025July 2025 Review & Safe Capital Investment Plans - newser.com
Applying Wyckoff theory to Amylyx Pharmaceuticals Inc. stockJuly 2025 Market Mood & Safe Swing Trade Setups - newser.com
Will Amylyx Pharmaceuticals Inc. price bounce be sustainable2025 Big Picture & Scalable Portfolio Growth Ideas - newser.com
Will Amylyx Pharmaceuticals Inc. stock deliver better than expected guidanceTrade Signal Summary & Safe Entry Momentum Stock Tips - newser.com
What’s the recovery path for long term holders of Amylyx Pharmaceuticals Inc.Weekly Market Outlook & Free Weekly Chart Analysis and Trade Guides - newser.com
Using portfolio simulators with Amylyx Pharmaceuticals Inc. includedTrade Volume Report & Short-Term Trading Opportunity Alerts - newser.com
Trend analysis for Amylyx Pharmaceuticals Inc. this weekPortfolio Return Report & Free Expert Approved Momentum Trade Ideas - newser.com
Is Amylyx Pharmaceuticals Inc. stock in correction or buying zoneJuly 2025 Review & Daily Technical Forecast Reports - newser.com
Y Intercept Hong Kong Ltd Purchases New Position in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
What analysts say about Amylyx Pharmaceuticals Inc stockEconomic Indicators Overview & Free Stay Ahead With Picks - earlytimes.in
Measuring Amylyx Pharmaceuticals Inc.’s beta against major indicesJuly 2025 Breakouts & Detailed Earnings Play Strategies - newser.com
Amylyx Pharmaceuticals (AMLX) Projected to Post Earnings on Thursday - MarketBeat
Using flow based indicators on Amylyx Pharmaceuticals Inc.July 2025 Update & AI Powered Market Entry Strategies - newser.com
Important Notice to Long-Term Shareholders of Amylyx - GlobeNewswire
Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 - Business Wire
Q3 Earnings Estimate for AMLX Issued By Lifesci Capital - MarketBeat
Amylyx Pharmaceuticals Advances Phase 3 Study for Post-Bariatric Hypoglycemia Treatment - MSN
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):